
Mantle Cell Lymphoma
Latest News
Video Series

Latest Videos
Shorts









Podcasts
CME Content
More News

Elise A. Chong, MD, discusses real-world liso-cel efficacy and safety, outpatient use, and future directions in relapsed/refractory mantle cell lymphoma.

Brad S. Kahl, MD, discusses TRIANGLE and EA4151 data reshaping ASCT use in frontline MCL, induction intensity, and high-risk disease strategies.

Data from a retrospective study showed high levels of CEACAM1 expression in patients with mantle cell lymphoma.

The phase 3 ECHO trial confirmed a durable progression-free survival benefit with frontline acalabrutinib-based therapy in mantle cell lymphoma.

Real-world tumor lysis syndrome occurred in less patients with CLL who received venetoclax-based regimens than those with MCL.

Signatera assay ctDNA testing showed stronger prognostic and predictive value than PET/CT imaging across lymphomas.

Alternating VR-CAP and rituximab plus cytarabine with continuous acalabrutinib produced deep responses and high MRD negativity in untreated MCL.

Tycel Phillips, MD, discusses sonrotoclax’s FDA approval for mantle cell lymphoma and why the BCL2 inhibitor opens more possibilities.

Experts break down SOHO 2026 and topics at the meeting that will shape hematologic oncology for the rest of the year.

Sonrotoclax monotherapy produced durable responses in Chinese patients with relapsed/refractory mantle cell lymphoma.

Marc S. Hoffmann, MD, discusses data for sonrotoclax plus zanubrutinib and unmet needs in the mantle cell lymphoma treatment paradigm.

Docirbrutinib generated responses in patients with relapsed/refractory CLL/SLL, MCL, and other non-Hodgkin lymphomas.

Obinutuzumab plus zanubrutinib produced high complete response rates with manageable toxicity in older patients with previously untreated mantle cell lymphoma.

Rocbrutinib elicited an overall response rate of 63.9% in covalent BTK inhibitor–pretreated relapsed/refractory mantle cell lymphoma.

A real-world claims analysis linked zanubrutinib to improved time to next treatment and overall survival vs acalabrutinib in relapsed/refractory MCL.

Zanubrutinib plus R-BAP produced responses in both younger and older patients with previously untreated mantle cell lymphoma.

Frontline zanubrutinib plus rituximab demonstrated significant efficacy compared with SOC chemoimmunotherapy in patients with mantle cell lymphoma.

Sonrotoclax plus zanubrutinib yielded deep, durable responses at the recommended phase 2 dose in relapsed/refractory MCL.

LB2501, an off-the-shelf in vivo dual-target CAR T-cell therapy, produced a 100% ORR at dose level 2 across DLBCL, MCL, and follicular lymphoma.





























































